Verastem Management

Management criteria checks 1/4

Verastem's CEO is Dan Paterson, appointed in Jun 2019, has a tenure of 4.83 years. total yearly compensation is $3.63M, comprised of 15% salary and 85% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $260.29K. The average tenure of the management team and the board of directors is 4 years and 2.6 years respectively.

Key information

Dan Paterson

Chief executive officer

US$3.6m

Total compensation

CEO salary percentage	15.0%
CEO tenure	4.8yrs
CEO ownership	0.1%
Management average tenure	4yrs
Board average tenure	2.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dan Paterson's remuneration changed compared to Verastem's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$4m	US$545k	-US$87m
Sep 30 2023	n/a	n/a	-US$77m
Jun 30 2023	n/a	n/a	-US$75m
Mar 31 2023	n/a	n/a	-US$73m
Dec 31 2022	US$698k	US$470k	-US$74m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$78m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$2m	US$460k	-US$71m
Sep 30 2021	n/a	n/a	-US$75m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$45m
Dec 31 2020	US$2m	US$467k	-US$68m
Sep 30 2020	n/a	n/a	-US$87m
Jun 30 2020	n/a	n/a	-US$130m
Mar 31 2020	n/a	n/a	-US$149m
Dec 31 2019	US$2m	US$445k	-US$149m

Compensation vs Market: Dan's total compensation ($USD3.63M) is above average for companies of similar size in the UK market ($USD760.97K).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.

CEO

Dan Paterson (62 yo)

4.8yrs

Tenure

US$3,626,857

Compensation

Mr. Daniel W. Paterson, also known as Dan, serves as Chief Executive Officer Verastem, Inc. since August 1, 2023 and is its President of Verastem, Inc. since June 2019. He is Director of Verastem, Inc. sin...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Daniel Paterson	President	4.8yrs	US$3.63m	0.11% $ 260.3k
Daniel Calkins	CFO and Principal Accounting & Financial Officer	1.5yrs	US$622.56k	0.024% $ 57.3k
Richard Aldrich	Founder and Consultant	9.6yrs	US$114.77k	no data
Robert Weinberg	Co-Founder & Chair of Scientific Advisory Board	no data	no data	no data
Piyush Gupta	Co-Founder	no data	no data	no data
Michelle Dipp	Co-Founder	no data	no data	no data
Robert Pintar	Senior Vice President of Technical Operations	3.3yrs	no data	no data
Jonathan Pachter	Chief Scientific Officer	8yrs	US$319.51k	no data
Nate Sanburn	Senior Vice President of Corporate Development & External Engagement	less than a year	no data	no data
Hagop Youssoufian	Head of Medical Strategy	7.3yrs	no data	no data
Cathy Carew	Chief Organizational Effectiveness Officer	no data	no data	no data
Stephanie Lustgarten	Senior Vice President of Data Sciences	1.3yrs	no data	no data

4.0yrs

Average Tenure

63.5yo

Average Age

Experienced Management: 0LOV's management team is considered experienced (4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Daniel Paterson	President	less than a year	US$3.63m	0.11% $ 260.3k
Robert Weinberg	Co-Founder & Chair of Scientific Advisory Board	no data	no data	no data
Mario Sznol	Member of Scientific Advisory Board	no data	no data	no data
Michael Kauffman	Lead Independent Director	11.4yrs	US$124.29k	0.0022% $ 5.2k
Paul A. Bunn	Independent Director	2.8yrs	US$74.29k	0% $ 0
Eric Rowinsky	Independent Director	6.9yrs	US$89.29k	0% $ 0
John Johnson	Independent Director	4yrs	US$81.29k	0% $ 0
Robert Gagnon	Director	1.3yrs	US$64.29k	0.083% $ 196.2k
Channing Der	Member of Scientific Advisory Board	2.1yrs	no data	no data
Brian Stuglik	Director	6.6yrs	US$2.30m	0.35% $ 840.8k
Anil Kapur	Independent Director	1.5yrs	US$81.75k	0% $ 0
Michelle Robertson	Independent Director	2.4yrs	US$84.29k	0% $ 0

2.6yrs

Average Tenure

63yo

Average Age

Experienced Board: 0LOV's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Verastem Management

Management criteria checks 1/4

Key information

Recent management updates

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Announces Executive Appointments

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Recent updates

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Launch of the New Healthcare Professional Component

Verastem, Inc. has filed a Follow-on Equity Offering in the amount of $6.510455 million.

Verastem Oncology Announces Executive Appointments

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $85.018462 million.

Verastem Oncology Announces 1-for-12 Reverse Stock Split to Satisfy the Price Requirement for Continued Listing on the Nasdaq Global Market

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Less than half of directors are independent

Verastem, Inc. announced that it expects to receive $59.995963 million in funding from BVF Partners L.P.

Verastem, Inc. announced that it expects to receive $60 million in funding

Verastem Oncology Appoints Rob Gagnon to the Board of Directors

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021)

Verastem Oncology Appoints Anil Kapur to Board of Directors

Verastem Oncology Announces RAMP VS-6766 Clinical Trials

Second quarter 2022 earnings released: US$0.12 loss per share (vs US$0.098 loss in 2Q 2021)

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 2000 Dynamic Index

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer

First quarter 2022 earnings released: US$0.091 loss per share (vs US$0.088 loss in 1Q 2021)

Less than half of directors are independent

Verastem, Inc., Annual General Meeting, May 12, 2022

Less than half of directors are independent

Full year 2021 earnings released: US$0.41 loss per share (vs US$0.44 loss in FY 2020)

Verastem, Inc. Announces Management Changes

CEO & Director recently sold US$53k worth of stock

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.078 profit in 3Q 2020)

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.098 loss per share (vs US$0.14 loss in 2Q 2020)

Forecast to breakeven in 2023

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 3000E Value Index

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

First quarter 2021 earnings released: US$0.088 loss per share (vs US$0.35 loss in 1Q 2020)

Verastem, Inc. Reports Updated Data from the LGSOC Cohort of the Ongoing, Investigator-Sponsored Phase 1/2 Frame Study Evaluating Vs-6766 in Combination with Defactinib in Patients with Recurrent LGSOC

Full year 2020 earnings released: US$0.44 loss per share (vs US$2.00 loss in FY 2019)

Verastem, Inc. Appoints Frank Neumann as Chief Medical Officer

Verastem, Inc. Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer

Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Secura Bio, Inc. completed the acquisition of Global Commercial and Development Rights of COPIKTRA from Verastem, Inc. (NasdaqGM:VSTM).

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age